Literature DB >> 3689632

A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

R G Watson1, W Bastain, K A Larkin, J R Hayes, J A McAinsh, R G Shanks.   

Abstract

1 Six male patients with alcoholic cirrhosis and seven normal control subjects were each given 80 mg twice daily of conventional propranolol for 1 week and 160 mg once daily of a long acting preparation (LA) of propranolol for 1 week. 2 Plasma propranolol levels were measured at regular intervals on the first and seventh days of both weeks and also following an acute intravenous infusion of 10 mg propranolol on a separate occasion. 3 After the single intravenous dose the elimination half-life tended to be prolonged in the cirrhotic group (median 7.15 h) compared with controls (median 2.92 h) (P = 0.055). 4 After multiple oral dosing with 80 mg twice daily of conventional propranolol the steady-state plasma concentration (Css), area under the curve (AUC tau), peak concentration (Cmax) and trough concentration (Cmin) were significantly higher in cirrhotic patients and the peak: trough ratio (Cmax/Cmin) was significantly lower than controls. 5 After multiple oral dosing with 160 mg LA once daily Cmin was significantly higher than Cmax/min significantly lower in cirrhotic patients; Css, AUC and Cmax were higher than controls but not statistically different. 6 Within both subject groups the bioavailability of 80 mg twice daily of conventional propranolol tended to be greater than 160 mg LA once daily. Cmax was significantly higher in both groups and Css higher in the cirrhotic group with conventional propranolol. 7 In the cirrhotic group the mean reduction in supine heart rate in the steady state was 31.8% with conventional 80 mg twice daily propranolol and 23.75% with 160 mg LA once daily.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689632      PMCID: PMC1386316          DOI: 10.1111/j.1365-2125.1987.tb03207.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Criteria for selection of patients for emergency portacaval shunt.

Authors:  M J Orloff; L R Duguay; L D Kosta
Journal:  Am J Surg       Date:  1977-07       Impact factor: 2.565

3.  Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

Authors:  H O Conn
Journal:  Am J Dig Dis       Date:  1977-06

4.  Effects of age and cigarette smoking on propranolol disposition.

Authors:  R E Vestal; A J Wood; R A Branch; D G Shand; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

5.  Pharmacology of propranolol in patients with cirrhosis and portal hypertension.

Authors:  M J Arthur; A R Tanner; C Patel; R Wright; A G Renwick; C F George
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

6.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration.

Authors:  A J Wood; D M Kornhauser; G R Wilkinson; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

8.  Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

9.  A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.

Authors:  R A Branch; J James; A E Read
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of propranolol.

Authors:  P A Routledge; D G Shand
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

View more
  10 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 2.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 4.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

5.  Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.

Authors:  P Calès; D Grasset; A Ravaud; C Meskens; M Blanc; J P Vinel; J Cotonat; J P Pascal
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

Review 6.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 7.  Safety of propranolol in portal hypertension. Conventional and long acting formulations.

Authors:  P C Hayes
Journal:  Drugs       Date:  1989       Impact factor: 9.546

8.  A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.

Authors:  Anne B Taegtmeyer; Manuel Haschke; Lydia Tchambaz; Mirabel Buylaert; Martin Tschöpl; Ulrich Beuers; Jürgen Drewe; Stephan Krähenbühl
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

9.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

10.  Systemic exposure to propranolol in patients with chronic liver disease and its correlation with portal blood flow.

Authors:  Tae-Eun Kim; Ju-Seop Kang; Wen An; Joo Hyun Sohn
Journal:  Front Med (Lausanne)       Date:  2022-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.